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Awareness of the importance of quality assurance in the 
ICU is growing but the methodology is still under 
development and subject to debate [1-3]. Ventilator-
associated pneumonia (VAP) seemed to come close to 
being an important, valid, reliable, responsive, inter-
pretable and feasible outcome parameter [3]. We there-
fore decided to measure VAP incidence on a regular 
basis. A prospective study was carried out with yearly 
assessment of the incidence of VAP during a 3-month 
period. Deﬁ  nition of VAP was based on the recommen-
dations of the Centers for Disease Control and Prevention 
[4]. Overall, out of 550 patients ventilated for >48 hours, 
only two cases of deﬁ   nite VAP were observed [5]. 
Because no further improvement could be achieved in 
this ﬁ   eld, we turned our attention to other outcome 
parameters. A perceived rise in incidence of VAP led us 
to repeat our evaluation, despite growing concern about 
the importance, validity and reliability of VAP as a quality 
indicator [2].
With the same methodology we measured the inci-
dence of VAP again. Compared to our previous research, 
we observed a signiﬁ  cant  (P < 0.001, chi-square test) 
increase in VAP in accordance with our impressions 
(Table 1).
Th  e incidence of VAP in our unit is still below that 
reported in the literature [2]. When used as a benchmark, 
we are performing well. However, when used as a quality 
indicator over time the results should lead to concern. 
Even if patients diagnosed with VAP do not have real 
VAP but colonization, atelectasis, or ﬂ  uid overload, these 
conditions are also detrimental for the patient and should 
be avoided [2].
As a benchmark, VAP incidence might have limited 
value [1,2]. Th   is is mainly due to inappropriate case mix 
correction and to diagnostic inaccuracy. Fear of being 
judged on disputable quality indicators such as inter-
hospital benchmarks is a serious threat to the probably 
valuable use of intra-hospital trend analysis of quality 
indicators. Used as a longitudinal quality indicator in a 
single centre, VAP is less threatened by case-mix 
diﬀ  erences and the limited sensitivity and speciﬁ  city of 
the VAP diagnostic criteria. Th  e price of this quality 
assessment is considerable. Th   e workload of this 14-week 
evaluation resulted in an estimated cost of 20,000 euros.
In our view, measurement of VAP incidence has its 
value as an intra-hospital quality indicator but not as a 
benchmark.
Abbreviations
VAP = ventilator-associated pneumonia.
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Table 1. Patients characteristics and results
Patients ventilated >48 hours (n)  169
Male:female 110:59
Medical ICU (n)  49
Surgical ICU (n)  55
Neuro-surgical ICU (n)  29
Cardio-thoracic ICU (n)  36
Age, years, median (range)  60 (21-84)
APACHE II score, median (range)  19 (12-36)
Length of ICU stay, days, median (range)  12 (2-103)
Ventilator days, median (range)  7 (2-91)
VAP, defi  nite (n)*  15
VAP, probable (n)† 12
Defi  nite VAP per 1,000 ventilator days (n)  7.5
Percentage patients with defi  nite VAP (%)  8.9%
ICU mortality, n (%)  34 (20%)
Mortality in patients with defi  nite VAP, n (%)  2 (13%)
*Defi  ned as based on Centers for Disease Control and Prevention criteria 
[4], with a new and persistent infi  ltrate on chest X-ray, a positive culture in 
trachea-aspirate or broncho-alveolar lavage, occurrence of purulent sputum, 
fever and/or leucocytosis or leucopenia as obligatory features. †Defi  ned as 
based on Centers for Disease Control and Prevention criteria [4]; all the same 
circumstances as above except a positive culture as the required parameters. 
VAP, ventilator-associated pneumonia.
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